W. L. Gore & Associates has won CE mark for the GORE hybrid vascular graft designed to expand treatment options for optimal outflow by maximizing the number of access sites available.
The GORE hybrid vascular graft is indicated for use as a vascular prosthesis for replacement or bypass of diseased vessels impacted by aortic aneurysmal, peripheral vascular and end stage renal disease.
The device, which is designed to address the common causes of graft failure; intimal hyperplasia, thrombosis, and seroma, simplifies access to vessels with an optional over the wire deployment method that reduces vessel injury and dissection.
The Methodist DeBakey Heart and Vascular Center in Houston, Texas, assistant professor Jean Bismuth said the GORE Hybrid Vascular Graft, for the first time, palpably bridges the gap between traditional vascular and endovascular surgery.
"The GORE Hybrid Vascular Graft allows the surgeon to create a sutureless anastomosis and displays significant potential for improving hemodynamics," Bismuth added.
The graft incorporates CARMEDA BioActive Surface (CBAS Surface) with covalently bonded heparin and preserves the amount of access sites available throughout the patient's long-term therapy.
The Gore Venous Access Business associate Chuck Biggerstaff said, "Receiving CE Mark for the GORE Hybrid Vascular Graft demonstrates our commitment to providing physicians with innovative technology that can expand treatment options and improve patient outcomes worldwide."
